Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06473610

Residual Embolism Evaluated With Single Photon Emission Computed Tomography

Major progress achieved in diagnostic and therapeutic strategies has substantially improved the short-term prognosis of patients with pulmonary embolism (PE). These improvements have led to a shift from an acute to a chronic condition of venous thromboembolism, justifying the recent development of Chronic Thrombo-embolic Disease (CTED). In most of the situations, it is due to a residual pulmonary vascular obstruction (RPVO) which can be assessed by pulmonary scintigraphy.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Pulmonary Circulation Obstruction

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Centre Hospitalier Universitaire

Saint-Etienne, 42055, France

Location status: Recruiting

Location contact

Nathalie PREVOT, MD

SUB_INVESTIGATOR

PIERRE-BENOIT BONNEFOY, MD

PRINCIPAL_INVESTIGATOR

About this study

Planar ventilation/perfusion (V/Q) scintigraphy is the gold standard, but for several months, V/Q single photon emission computed tomography (SPECT) is recommended in the guidelines.

The aim of this study is to evaluate the performances of various SPECT protocols to quantified RPVO and compared to planar scintigraphy to evaluate the RPVO.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient addressed to nuclear medicine department of Saint-Etienne public hospital for V/Q pulmonary SPECT-CT assess to rule out perfusion obstruction, admitted for a suspicion of pulmonary hypertension (PH), or a persistent dyspnea after PE
  • Patient affiliated ou beneficiary of social security.

Exclusion criteria

  • Pregnant patient.
  • Patient addressed to nuclear medicine department for acute pulmonary embolism.
  • Impossibility of the entire protocol acquisitions realization.

Treatment and study plan

Primary outcomes

  1. RPVO (%)

    Time frame: At inclusion

    Evaluation of the RPVO establish with Meyer score (planar scintigraphy, 2D). The higher the percentage, the greater the obstruction of the lung

  2. Segmental visual score

    Time frame: At inclusion

    Evaluation of segmental visual score (SPECT-CT , 3D) The higher the percentage, the greater the obstruction of the lung

Study contacts

Contact information is provided by the study sponsor or research team.

NATHALIE PREVOT, MD

CONTACT

[email protected]

(0)4 77 82 94 43 ext. +33

Pierre-Benoit BONNEFOY, MD

CONTACT

[email protected]

(0)4 77 82 94 43 ext. +33

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Saint Etienne

Other

Registry information

Official study title

Residual Embolism Evaluated With Single Photon Emission Computed Tomography - The RESPECT Cohort

Acronym: RESPECT

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jun 25, 2024
Registry last updated
Aug 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.